EBS
Price
$8.16
Change
-$0.63 (-7.17%)
Updated
Dec 18, 04:59 PM (EDT)
63 days until earnings call
MKGAF
Price
$145.80
Change
+$1.37 (+0.95%)
Updated
Dec 18 closing price
Ad is loading...

EBS vs MKGAF

Header iconEBS vs MKGAF Comparison
Open Charts EBS vs MKGAFBanner chart's image
Emergent Biosolutions
Price$8.16
Change-$0.63 (-7.17%)
Volume$16.9K
CapitalizationN/A
Merck KGaA
Price$145.80
Change+$1.37 (+0.95%)
Volume$593
CapitalizationN/A
EBS vs MKGAF Comparison Chart
Loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EBS vs. MKGAF commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EBS is a Hold and MKGAF is a StrongBuy.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (EBS: $8.16 vs. MKGAF: $145.80)
Brand notoriety: EBS and MKGAF are both not notable
Both companies represent the Pharmaceuticals: Other industry
Current volume relative to the 65-day Moving Average: EBS: 110% vs. MKGAF: 154%
Market capitalization -- EBS: $120.07M vs. MKGAF: $76.59B
EBS [@Pharmaceuticals: Other] is valued at $120.07M. MKGAF’s [@Pharmaceuticals: Other] market capitalization is $76.59B. The market cap for tickers in the [@Pharmaceuticals: Other] industry ranges from $77.48B to $0. The average market capitalization across the [@Pharmaceuticals: Other] industry is $3.53B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EBS’s FA Score shows that 1 FA rating(s) are green whileMKGAF’s FA Score has 1 green FA rating(s).

  • EBS’s FA Score: 1 green, 4 red.
  • MKGAF’s FA Score: 1 green, 4 red.
According to our system of comparison, EBS is a better buy in the long-term than MKGAF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EBS’s TA Score shows that 3 TA indicator(s) are bullish while MKGAF’s TA Score has 5 bullish TA indicator(s).

  • EBS’s TA Score: 3 bullish, 6 bearish.
  • MKGAF’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, MKGAF is a better buy in the short-term than EBS.

Price Growth

EBS (@Pharmaceuticals: Other) experienced а -4.78% price change this week, while MKGAF (@Pharmaceuticals: Other) price change was -2.31% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +0.75%. For the same industry, the average monthly price growth was +1.64%, and the average quarterly price growth was -9.20%.

Reported Earning Dates

EBS is expected to report earnings on Feb 20, 2025.

Industries' Descriptions

@Pharmaceuticals: Other (+0.75% weekly)

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MKGAF($76.6B) has a higher market cap than EBS($120M). MKGAF has higher P/E ratio than EBS: MKGAF (20.96) vs EBS (17.73). EBS YTD gains are higher at: 266.250 vs. MKGAF (-10.295). MKGAF has higher annual earnings (EBITDA): 6.45B vs. EBS (-518.2M). MKGAF has more cash in the bank: 1.72B vs. EBS (112M). EBS has less debt than MKGAF: EBS (860M) vs MKGAF (10.6B). MKGAF has higher revenues than EBS: MKGAF (22.3B) vs EBS (1.02B).
EBSMKGAFEBS / MKGAF
Capitalization120M76.6B0%
EBITDA-518.2M6.45B-8%
Gain YTD266.250-10.295-2,586%
P/E Ratio17.7320.9685%
Revenue1.02B22.3B5%
Total Cash112M1.72B7%
Total Debt860M10.6B8%
FUNDAMENTALS RATINGS
EBS vs MKGAF: Fundamental Ratings
EBS
MKGAF
OUTLOOK RATING
1..100
664
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
27
Undervalued
PROFIT vs RISK RATING
1..100
10074
SMR RATING
1..100
9671
PRICE GROWTH RATING
1..100
3679
P/E GROWTH RATING
1..100
1164
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MKGAF's Valuation (27) in the null industry is somewhat better than the same rating for EBS (66) in the Biotechnology industry. This means that MKGAF’s stock grew somewhat faster than EBS’s over the last 12 months.

MKGAF's Profit vs Risk Rating (74) in the null industry is in the same range as EBS (100) in the Biotechnology industry. This means that MKGAF’s stock grew similarly to EBS’s over the last 12 months.

MKGAF's SMR Rating (71) in the null industry is in the same range as EBS (96) in the Biotechnology industry. This means that MKGAF’s stock grew similarly to EBS’s over the last 12 months.

EBS's Price Growth Rating (36) in the Biotechnology industry is somewhat better than the same rating for MKGAF (79) in the null industry. This means that EBS’s stock grew somewhat faster than MKGAF’s over the last 12 months.

EBS's P/E Growth Rating (11) in the Biotechnology industry is somewhat better than the same rating for MKGAF (64) in the null industry. This means that EBS’s stock grew somewhat faster than MKGAF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EBSMKGAF
RSI
ODDS (%)
Bearish Trend 6 days ago
87%
Bullish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
83%
Bullish Trend 2 days ago
67%
Momentum
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
64%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
78%
Bearish Trend 2 days ago
61%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
67%
Advances
ODDS (%)
Bullish Trend 20 days ago
79%
Bullish Trend 9 days ago
63%
Declines
ODDS (%)
Bearish Trend 8 days ago
88%
Bearish Trend 3 days ago
59%
BollingerBands
ODDS (%)
N/A
Bullish Trend 2 days ago
54%
Aroon
ODDS (%)
Bullish Trend 2 days ago
76%
Bearish Trend 2 days ago
59%
View a ticker or compare two or three
Ad is loading...
EBS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
MKGAF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SSVRF0.200.01
+3.35%
Summa Silver Corp.
BYDDY68.991.81
+2.69%
BYD Co., Ltd.
NNGRY21.88-0.19
-0.86%
NN Group NV
KNYJY25.03-0.27
-1.07%
Kone Oyj
FPAFY3.00-0.05
-1.58%
First Pacific Company Ltd.

EBS and

Correlation & Price change

A.I.dvisor tells us that EBS and AMRX have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that EBS and AMRX's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EBS
1D Price
Change %
EBS100%
-0.90%
AMRX - EBS
31%
Poorly correlated
+4.13%
ZOM - EBS
29%
Poorly correlated
+0.91%
SNDL - EBS
27%
Poorly correlated
+4.17%
ACET - EBS
27%
Poorly correlated
-0.75%
HROW - EBS
26%
Poorly correlated
-4.27%
More

MKGAF and

Correlation & Price change

A.I.dvisor indicates that over the last year, MKGAF has been loosely correlated with MKKGY. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if MKGAF jumps, then MKKGY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MKGAF
1D Price
Change %
MKGAF100%
+0.86%
MKKGY - MKGAF
49%
Loosely correlated
-0.54%
AQST - MKGAF
19%
Poorly correlated
+6.94%
INDV - MKGAF
17%
Poorly correlated
-1.90%
EVO - MKGAF
17%
Poorly correlated
+2.36%
EBS - MKGAF
16%
Poorly correlated
-0.90%
More